Portal de Periódicos da CAPES

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

2008; Lippincott Williams & Wilkins; Volume: 179; Issue: 4 Linguagem: Inglês

10.1016/j.juro.2007.11.049

1527-3792

Chris Mullins, M. Scott Lucia, Simon W. Hayward, Jeannette Y. Lee, Jonathan M. Levitt, Victor K. Lin, Brian C.‐S. Liu, Arul M. Chinnaiyan, Mark A. Rubin, Kevin M. Slawin, Robert A. Star, Robert H. Getzenberg,

Alcohol Consumption and Health Effects

No AccessJournal of UrologyReview Article1 Apr 2008A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium Chris Mullins, M. Scott Lucia, Simon W. Hayward, Jeannette Y. Lee, Jonathan M. Levitt, Victor K. Lin, Brian C.-S. Liu, Arul M. Chinnaiyan, Mark A. Rubin, Kevin Slawin, Robert A. Star, Robert H. Getzenberg, and MPSA Consortium Chris MullinsChris Mullins National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland Financial interest and/or other relationship with AUA Research Council. More articles by this author , M. Scott LuciaM. Scott Lucia Prostate Diagnostic Laboratory and MPSA Pathology Coordinating Center, Department of Pathology, University of Colorado Denver and Health Sciences Center, Aurora, Colorado Financial interest and/or other relationship with GlaxoSmithKline and Veridex. More articles by this author , Simon W. HaywardSimon W. Hayward Departments of Urologic Surgery and Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee More articles by this author , Jeannette Y. LeeJeannette Y. Lee Medical Statistics Section, The University of Alabama at Birmingham, Birmingham, Alabama More articles by this author , Jonathan M. LevittJonathan M. Levitt Scott Department of Urology, Baylor College of Medicine, Houston, Texas Department of Immunology, Baylor College of Medicine, Houston, Texas Baylor College of Medicine, Houston, Texas More articles by this author , Victor K. LinVictor K. Lin Department of Urology, The University of Texas, Southwest Medical Center, Dallas, Texas More articles by this author , Brian C.-S. LiuBrian C.-S. Liu Molecular Urology Laboratory, Brigham and Women’s Hospital, Boston, Massachusetts More articles by this author , Arul M. ChinnaiyanArul M. Chinnaiyan Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts Financial interest and/or other relationship with Compendia, Gen-Probe and Rubicon. More articles by this author , Mark A. RubinMark A. Rubin Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts More articles by this author , Kevin SlawinKevin Slawin Scott Department of Urology, Baylor College of Medicine, Houston, Texas Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author , Robert A. StarRobert A. Star National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland More articles by this author , Robert H. GetzenbergRobert H. Getzenberg James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland Financial interest and/or other relationship with University of Pittsburgh and Johns Hopkins University. More articles by this author , and MPSA Consortium More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2007.11.049AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Clinical benign prostatic hyperplasia is primarily diagnosed based on a diverse array of progressive lower urinary tract symptoms and is likely distinct from histological benign prostatic hyperplasia, which is detected by the presence of nonmalignant proliferation of prostate cells but may or may not be associated with symptoms. Pharmacological management of lower urinary tract symptoms has emerged as an effective initial treatment for clinical benign prostatic hyperplasia due to the introduction of new drug therapies shown to be effective in recent large clinical trials. Despite advances in symptom management and research into disease pathology, diagnostic strategies for the prediction of benign prostatic hyperplasia progression and response to drug modalities are lacking, and questions remain as to the molecular differences underlying clinical (symptomatic) vs histological (nonsymptomatic) benign prostatic hyperplasia. Materials and Methods: As part of the Medical Therapy of Prostatic Symptoms (MTOPS) clinical trial, which demonstrated the effectiveness of combination drug therapy in slowing benign prostatic hyperplasia progression, an archive of biological specimens linked to clinical data was collected for future profiling of disease pathology and changes associated with response to drug therapy. The MTOPS Prostatic Samples Analysis (MPSA) Consortium was established to identify and validate molecular markers that may better define benign prostatic hyperplasia related pathologies, identify risk of progression of lower urinary tract symptoms, and predict response to drug therapy using the MTOPS archive. The cooperating MPSA Biomarker Discovery Sites and Pathology Coordinating Center use diverse methodologies and scientific approaches as well as unique expertise to address the goals of the Consortium. Results: To date the MPSA has identified a number of promising biomarkers as well as other molecular and cellular changes associated with benign prostatic hyperplasia. Conclusions: These findings and ongoing Consortium discovery efforts have the potential to provide a greater understanding of the defects underlying disease pathology, and may lead to the development of early and more effective pharmacological treatment strategies for benign prostatic hyperplasia. References 1 : Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol2002; 42: 1. Google Scholar 2 : BPH: epidemiology and comorbidities. Am J Manag Care2006; 12: S122. Google Scholar 3 : Urologic Diseases in America Project: benign prostatic hyperplasia. J Urol2005; 173: 1256. Link, Google Scholar 4 : A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol2003; 173: 2048. Google Scholar 5 : Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int2004; 94: 738. Google Scholar 6 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Google Scholar 7 : Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol2004; 15: 1677. Google Scholar 8 : Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials2001; 22: 485. Google Scholar 9 : Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem1998; 100: 439. Google Scholar 10 : Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int1999; 84: 976. Google Scholar 11 : Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol2003; 43: 164. Google Scholar 12 : Immune response in hormonally-induced prostatic hyperplasia in the dog. Vet Immunol Immunopathol2001; 78: 297. Google Scholar 13 : Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A2002; 99: 7598. Google Scholar 14 : The ‘reverse capture’ autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc2006; 1: 452. Google Scholar 15 : Development of a “reverse capture” autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics2006; 6: 3199. Google Scholar 16 : Citron rho-interacting kinase, a novel tissue-specific ser/thr kinase encompassing the Rho-Rac-binding protein Citron. J Biol Chem1998; 273: 29706. Google Scholar 17 : Citron kinase, a Rho-dependent kinase, induces di-phosphorylation of regulatory light chain of myosin II. Mol Biol Cell2003; 14: 1745. Google Scholar 18 : Mouse urogential development: a practical approach. Differentiation2003; 71: 402. Google Scholar 19 : Androgen regulation of JM-27 is associated with the diseased prostate. J Androl2004; 25: 618. Google Scholar 20 : Benign prostatic hyperplasia cell viability and modulation of JM-27 by doxazosin and ibuprofen. J Urol2005; 174: 375. Link, Google Scholar 21 : A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. J Urol2007; 177: 610. Link, Google Scholar 22 : Molecular cloning of human prostate specific antigen cDNA. FEBS Lett1987; 214: 317. Google Scholar 23 : A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res1991; 51: 222. Google Scholar 24 : “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology2000; 55: 41. Google Scholar 25 : Free prostate-specific antigen in serum is becoming more complex. Urology2002; 59: 797. Google Scholar 26 : BPSA: a novel serum marker for benign prostatic hyperplasia. Rev Urol2005; 7: S52. Google Scholar 27 : Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression. Curr Prostate Rep2007; 5: 21. Google Scholar 28 : Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem2003; 49: 253. Google Scholar 29 : Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology2004; 63: 905. Google Scholar 30 : Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol2004; 6: 58. Google Scholar 31 : Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?. Eur Urol2000; 38: 91. Google Scholar 32 : Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol2004; 46: 488. Google Scholar 33 : Prediction of prostate volume using molecular forms of PSA in men with BPH enrolled on the GSK Phase III Dutasteride Trials. J Urol2006; 175: 439. abstract 1363. Link, Google Scholar 34 : The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol1992; 148: 1549. Abstract, Google Scholar 35 : Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care1995; 33: AS145. Google Scholar 36 : Baseline serum BPH-A level enhances the accuracy of a nomogram to predict BPH progression in men enrolled on the GSK Phase III Dutasteride Trials. J Urol2006; 175: 436. abstract 1352. Link, Google Scholar 37 : Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. Urology2006; 67: 84. Google Scholar 38 : CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord2005; 5: 109. Google Scholar 39 : Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol2005; 68: 149. Google Scholar 40 : Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene2006; 25: 7469. Google Scholar 41 : F3/contactin, a neuronal cell adhesion molecule implicated in axogenesis and myelination. Biol Cell2002; 94: 327. Google Scholar 42 : F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell2003; 115: 163. Google Scholar 43 : Cross-talk between F3/contactin and Notch at axoglial interface: a role in oligodendrocyte development. Dev Neurosci2006; 28: 25. Google Scholar 44 : Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. Hum Pathol1993; 24: 982. Google Scholar 45 : Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate1997; 32: 214. Google Scholar 46 : The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med1998; 338: 557. Google Scholar 47 : Management of symptomatic BPH in the US: who is treated and how?. Eur Urol1999; 36: 7. Google Scholar 48 : Integrative molecular concept modeling of prostate cancer progression. Nat Genet2007; 39: 41. Google Scholar 49 : Whole transcriptome amplification for gene expression profiling and development of molecular archives. Neoplasia2006; 8: 153. Google Scholar 50 : A native antigen reverse capture microarray platform for autoantibody profiling of prostate cancer sera. Proteomics Clin Appl2007; 1: 476. Google Scholar © 2008 by American Urological AssociationFiguresReferencesRelatedDetailsCited byBechis S, Otsetov A, Ge R and Olumi A (2018) Personalized Medicine for the Management of Benign Prostatic HyperplasiaJournal of Urology, VOL. 192, NO. 1, (16-23), Online publication date: 1-Jul-2014.Rhodes T, Jacobson D, McGree M, St. Sauver J, Sarma A, Girman C, Lieber M, Klee G, Demissie K and Jacobsen S (2018) Benign Prostate Specific Antigen Distribution and Associations With Urological Outcomes in Community Dwelling Black and White MenJournal of Urology, VOL. 187, NO. 1, (87-91), Online publication date: 1-Jan-2012. Volume 179Issue 4April 2008Page: 1243-1256 Advertisement Copyright & Permissions© 2008 by American Urological AssociationKeywordsprostatic hyperplasiabiological markersurologic diseasesMetricsAuthor Information Chris Mullins National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland Financial interest and/or other relationship with AUA Research Council. More articles by this author M. Scott Lucia Prostate Diagnostic Laboratory and MPSA Pathology Coordinating Center, Department of Pathology, University of Colorado Denver and Health Sciences Center, Aurora, Colorado Financial interest and/or other relationship with GlaxoSmithKline and Veridex. More articles by this author Simon W. Hayward Departments of Urologic Surgery and Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee More articles by this author Jeannette Y. Lee Medical Statistics Section, The University of Alabama at Birmingham, Birmingham, Alabama More articles by this author Jonathan M. Levitt Scott Department of Urology, Baylor College of Medicine, Houston, Texas Department of Immunology, Baylor College of Medicine, Houston, Texas Baylor College of Medicine, Houston, Texas More articles by this author Victor K. Lin Department of Urology, The University of Texas, Southwest Medical Center, Dallas, Texas More articles by this author Brian C.-S. Liu Molecular Urology Laboratory, Brigham and Women’s Hospital, Boston, Massachusetts More articles by this author Arul M. Chinnaiyan Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts Financial interest and/or other relationship with Compendia, Gen-Probe and Rubicon. More articles by this author Mark A. Rubin Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts More articles by this author Kevin Slawin Scott Department of Urology, Baylor College of Medicine, Houston, Texas Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author Robert A. Star National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland More articles by this author Robert H. Getzenberg James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland Financial interest and/or other relationship with University of Pittsburgh and Johns Hopkins University. More articles by this author MPSA Consortium More articles by this author Expand All Advertisement PDF downloadLoading ...